The INFORM-MM study
Living with multiple myeloma?
Your perspective matters.
This study explores how patients and myeloma specialists think about MRD testing and how results may affect treatment decisions. Your input could help shape future myeloma care.
What is MRD testing?
MRD stands for minimal residual disease. MRD testing looks for very small amounts of myeloma cells in the bone marrow that may remain after treatment.
This study uses MRD testing already planned as part of your regular care. You will not need any extra MRD testing to participate in this study.
You may be able to join if you:
- Have multiple myeloma
- Are 18 years or older
- Have MRD testing planned as part of your regular care
- Can complete surveys online or by phone
- Are not currently enrolled in a clinical trial
-
Share your views
Complete online surveys about MRD testing, your preferences, and your quality of life. Surveys will take about 10–15 minutes to complete. You can also choose to include a care partner.
-
Take part over time
About 6 months or 1 year, depending on your treatment and MRD testing schedule.
-
Receive compensation
You will be compensated up to $350 for your time and participation.
Interested? Learn more.
Find a participating clinic
Contact the study team at your clinic to ask about INFORM-MM, or start joining online.
1 clinic listed
- Demo Clinic
- Study contact:Smoke 390 NoJS 18345
- Call555-010-2000
- Emailstudy@smoke.example
Questions? Reach out to us.
We're happy to tell you more about the study before you decide.
Available at participating sites. Funding provided by Adaptive Biotechnologies.